Immunocore
IMCR | NASDAQ
$28.88
-$1.06 (-3.54%)
At close: Nov 16, 2026, 4:00 PM ET
$28.88
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 6:41 PM ET
Immunocore Company Profile
Company profile explainedCompany Profile
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Key Executives
| Name | Position |
|---|---|
| Bahija Jallal | Chief Executive Officer & Executive Director |
| Kripa Ram | Executive VP & Chief Operating Officer |
| Sean D. Buckley | Vice President & Chief Information Officer |
| Travis A. Coy | Chief Financial Officer, Executive Vice President & Head of Corporate Development |
| Anne Achola Sefu | EVP, Chief Human Resources Officer & Director |
| Annelise Vuidepot | Chief Science and Technology Officer & Milton Park Site Head |
| Elizabeth Varki Jobes | Chief Compliance Officer |
| John Goll | SVP, Finance & Chief Accounting Officer |
| Lily Margaret Hepworth | Executive Vice President, General Counsel & Company Secretary |
| Ryan Baker | Vice President of Investor Relations |
| Sébastien Desprez | Vice President of Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| May 28, 2026 | 4 | Filing |
| May 28, 2026 | 4 | Filing |
| May 28, 2026 | 4 | Filing |
Immunocore
| Country | United Kingdom |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 524 |
| CEO | Bahija Jallal |
Contact Details
92 Park Drive Abingdon,
OX OX14 4RY United Kingdom
Stock Details
| Ticker Symbol | IMCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671927 |
| CUSIP Number | 45258D105 |
| ISIN Number | US45258D1054 |
| SIC Code | 2836 |
Recent News
- 8 days ago / globenewswire.comImmunocore to present at upcoming investor conferences
- 11 days ago / globenewswire.comImmunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
- 11 days ago / globenewswire.comImmunocore reports third quarter financial results and provides a business update
- 19 days ago / globenewswire.comImmunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
- 1 month ago / globenewswire.comImmunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
- 2 months ago / zacks.comImmunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
- 2 months ago / seekingalpha.comImmunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / globenewswire.comImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
- 3 months ago / zacks.comWill Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
- 3 months ago / zacks.comIMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Add to Watchlist
Select watchlists to add or remove IMCR